MannKind Corporation (MNKD) is a Biotechnology company in the Healthcare sector, currently trading at $2.74. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of MNKD = $12.62 (+360.6% from the current price, the stock appears undervalued). Analyst consensus target is MNKD = $9 (+228.5% upside).
Valuation: MNKD trades at a trailing Price-to-Earnings (P/E) of 136.2 (S&P 500 average ~25).
Financials: revenue is $349M, +55%/yr average growth. Net income is $6M, growing at +113.9%/yr. Net profit margin is 1.7% (thin). Gross margin is 82.5% (+40.1 pp trend).
Balance sheet: total debt is $473M with negative equity of -$51M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 1.7 (strong liquidity). Debt-to-assets is 59.8%. Total assets: $792M.
Analyst outlook: 8 / 18 analysts rate MNKD as buy (44%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 62/100 (Pass), Growth 100/100 (Pass), Past 50/100 (Partial), Health 50/100 (Partial), Moat 64/100 (Partial), Future 52/100 (Partial), Income 30/100 (Fail).
